N-Terminal Pro–B-Type Natriuretic Peptide Levels for Dynamic Risk Stratification of Patients With Acute Coronary Syndromes

Background—Elevated baseline levels of B-type natriuretic peptide (BNP) and the N-terminal fragments of its prohormone, N-terminal-pro-BNP (NT-proBNP), have been associated with adverse long-term outcome in patients with acute coronary syndromes, whereas the prognostic implications of serial NT-proBNP measurements have not been investigated to date. Methods and Results—NT-proBNP, troponin T, and C-reactive protein were measured at baseline and at 48 and 72 hours in 1791 patients with non–ST-elevation acute coronary syndromes. Death and myocardial infarction were recorded during 30 days of follow-up. After adjustment for independent predictors of cardiac risk, baseline NT-proBNP levels >250 ng/L were associated with higher event rates (adjusted OR, 3.7; 95% CI, 2.3 to 5.7; P<0.001). In troponin T–negative patients, NT-proBNP identified a subgroup of high-risk patients (OR, 5.9; 95% CI, 2.6 to 13.3; P<0.001). The risk in those patients (7.2%) did not significantly differ from that in troponin T–positive patients (9.8%; P=0.25). Importantly, clinical stabilization without refractory ischemia was associated with a rapid (as soon as 48 hours after onset of symptoms) and significant (48 hours; −24%; 72 hours, −49%; both P<0.001) decline in NT-proBNP levels. In patients with high NT-proBNP baseline levels, lack of a rapid decline in NT-proBNP levels (≤250 ng/L) was linked to an adverse short-term prognosis (OR, 33.7; 95% CI, 8.2 to 138.8; P<0.001). In patients with low NT-proBNP baseline levels, a rise in NT-proBNP levels over 72 hours to >250 ng/L was also linked to an adverse 30-day prognosis (OR, 24.0; 95% CI, 8.4 to 68.5; P<0.001). Conclusions—Neurohumoral activation as evidenced by NT-proBNP appears as a unifying feature that is independent of other biochemical markers (myocardial necrosis, inflammation) and is a powerful and independent determinant of the short-term cardiac risk in patients with acute coronary syndromes. Whether serial measurements of NT-proBNP in patients with ACS may be used to more rapidly identify patients suitable for early discharge or more intensive therapy deserves future prospective studies.

[1]  M. LeWinter,et al.  Increased Atrial and Brain Natriuretic Peptides in Adults With Cyanotic Congenital Heart Disease: Enhanced Understanding of the Relationship Between Hypoxia and Natriuretic Peptide Secretion , 2004, Circulation.

[2]  M. Vogeser,et al.  Clinical significance of brain natriuretic peptide in primary pulmonary hypertension. , 2004, Journal of the American College of Cardiology.

[3]  K. Bibbins-Domingo,et al.  B-Type Natriuretic Peptide and Ischemia in Patients With Stable Coronary Disease: Data From the Heart and Soul Study , 2003, Circulation.

[4]  H. White,et al.  Use of brain natriuretic peptide levels for risk assessment in non-ST-elevation acute coronary syndromes. , 2003, Journal of the American College of Cardiology.

[5]  R. Califf,et al.  N‐Terminal Pro‐Brain Natriuretic Peptide and Other Risk Markers for the Separate Prediction of Mortality and Subsequent Myocardial Infarction in Patients With Unstable Coronary Artery Disease: A Global Utilization of Strategies To Open occluded arteries (GUSTO)‐IV Substudy , 2003, Circulation.

[6]  H. Büller,et al.  Brain Natriuretic Peptide as a Predictor of Adverse Outcome in Patients With Pulmonary Embolism , 2003, Circulation.

[7]  M. Sabatine,et al.  Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18. , 2003, Journal of the American College of Cardiology.

[8]  A. Siegbahn,et al.  N-terminal pro-brain natriuretic peptide in relation to inflammation, myocardial necrosis, and the effect of an invasive strategy in unstable coronary artery disease. , 2003, Journal of the American College of Cardiology.

[9]  J. Herlitz,et al.  N-Terminal Pro-B-Type Natriuretic Peptide and Long-Term Mortality in Acute Coronary Syndromes , 2002, Circulation.

[10]  Carl J Pepine,et al.  ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients , 2002, Journal of the American College of Cardiology.

[11]  B. Lindahl,et al.  N-terminal pro brain natriuretic peptide on admission for early risk stratification of patients with chest pain and no ST-segment elevation. , 2002, Journal of the American College of Cardiology.

[12]  Nader Rifai,et al.  Multimarker Approach to Risk Stratification in Non-ST Elevation Acute Coronary Syndromes: Simultaneous Assessment of Troponin I, C-Reactive Protein, and B-Type Natriuretic Peptide , 2002, Circulation.

[13]  E. Antman,et al.  Prognostic value of N-terminal pro-atrial and pro-brain natriuretic peptide in patients with acute coronary syndromes. , 2002, The American journal of cardiology.

[14]  E. Braunwald,et al.  Acute coronary syndrome without ST elevation: implementation of new guidelines , 2001, The Lancet.

[15]  M. Sabatine,et al.  The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. , 2001, The New England journal of medicine.

[16]  C. Vassanelli,et al.  [Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban]. , 2001, Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology.

[17]  V. Hasselblad,et al.  Benefit of Glycoprotein IIb/IIIa Inhibition in Patients With Acute Coronary Syndromes and Troponin T–Positive Status: The PARAGON-B Troponin T Substudy , 2001, Circulation.

[18]  J. Boeynaems,et al.  Analyzer transfer of a broad range high-sensitivity C-reactive protein immunoassay. , 2001, Clinical laboratory.

[19]  M. Ohyanagi,et al.  Transient increase in plasma brain (b‐type) natriuretic peptide after percutaneous transluminal coronary angioplasty , 2000, Clinical cardiology.

[20]  J. W. Schaeffer,et al.  ACC/AHA guidelines for the management of patients with unstable angina and non‐ST segment elevation myocardial infarction: Executive summary and recommendations , 2000, Circulation.

[21]  E. Braunwald,et al.  A classification of unstable angina revisited. , 2000, Circulation.

[22]  H. White,et al.  Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban , 1999, The Lancet.

[23]  C. Heeschen,et al.  Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators. , 1999, The New England journal of medicine.

[24]  W. Shimizu,et al.  Diagnostic value of plasma levels of brain natriuretic peptide in arrhythmogenic right ventricular dysplasia. , 1998, Circulation.

[25]  R. Califf,et al.  Rationale and clinical evidence for the use of GP IIb/IIIa inhibitors in acute coronary syndromes. , 1998, European heart journal.

[26]  A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. , 1998, The New England journal of medicine.

[27]  A. Remppis,et al.  Improved troponin T ELISA specific for cardiac troponin T isoform: assay development and analytical and clinical validation. , 1997, Clinical chemistry.

[28]  H. Itoh,et al.  Rapid ventricular induction of brain natriuretic peptide gene expression in experimental acute myocardial infarction. , 1995, Circulation.

[29]  M. Hamada,et al.  Increased secretion of atrial and brain natriuretic peptides during acute myocardial ischaemia induced by dynamic exercise in patients with angina pectoris. , 1995, Clinical science.

[30]  D.,et al.  Regression Models and Life-Tables , 2022 .